HKPD
HealthcareCellyan Biotechnology Co., Ltd · Medical - Pharmaceuticals · $10M
HKPD — Key Takeaways
✅ Strengths
⚠️ Areas of Concern
HKPD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | 21.8 | 26.3 | 8.0 | 20.9 | 60.4 | 0.0 | +0.2 |
| Apr 7, 2026 | 21.6 | 25.2 | 8.0 | 20.9 | 60.4 | 0.0 | +0.1 |
| Apr 6, 2026 | 21.5 | 25.0 | 8.0 | 20.9 | 60.4 | 0.0 | 0.0 |
| Apr 5, 2026 | 21.5 | 25.0 | 8.0 | 20.9 | 60.4 | 0.0 | 0.0 |
| Apr 4, 2026 | 21.5 | 25.0 | 8.0 | 20.9 | 60.4 | 0.0 | 0.0 |
| Apr 3, 2026 | 21.5 | 25.0 | 8.0 | 20.9 | 60.4 | 0.0 | 0.0 |
| Apr 2, 2026 | 21.5 | 25.0 | 8.0 | 20.9 | 60.4 | 0.0 | — |
HKPD — Pillar Breakdown
Quality
— 26.3/100 (25%)Cellyan Biotechnology Co., Ltd currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 20.9/100 (20%)Cellyan Biotechnology Co., Ltd faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 60.4/100 (15%)Cellyan Biotechnology Co., Ltd maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Cellyan Biotechnology Co., Ltd appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 8/100 (30%)Cellyan Biotechnology Co., Ltd operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HKPD.
Score Composition
More Stock Analysis
How is the HKPD UQS Score Calculated?
The UQS (Unified Quality Score) for Cellyan Biotechnology Co., Ltd is calculated using a proprietary 5-pillar framework with 25 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Cellyan Biotechnology Co., Ltd's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Cellyan Biotechnology Co., Ltd is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.